Based on these data, 17p13 deletion is the sole cytogenetic abnormality that is recommended to be tested by FISH in CLL patients requiring treatment.2 Since CLL with TP53 mutations experience poor prognosis regardless of the presence of 17p13 deletion, the TP53 mutation analysis should be integrated into the evaluation of CLL patients before treatment initiation.44 CLL patients carrying TP53 alterations, regardless of whether mutated or deleted, should be redirected to different therapeutic regimens compared to the standard chemo/chemoimmuno-therapies.2,33,35,44,46. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.